Sunshine Biopharma (SBFMW) Net Income towards Common Stockholders (2011 - 2026)

Sunshine Biopharma has reported Net Income towards Common Stockholders for 14 years, with the latest figure at -$1.2 million in Q1 2026.

• For the quarter ending Q1 2026, Net Income towards Common Stockholders fell 5.43% year-over-year to -$1.2 million; the trailing twelve-month figure through Mar 2026 stood at -$6.0 million (up 4.35% YoY), and the FY2025 full-year result was -$6.0 million, down 16.39% from the prior year.
• Net Income towards Common Stockholders for Q1 2026 stood at -$1.2 million, up from -$2.1 million in the prior quarter.
• The five-year high for Net Income towards Common Stockholders was $295951.0 in Q3 2025, with the low at -$23.5 million in Q4 2022.
• Historically, Net Income towards Common Stockholders has averaged -$2.6 million across 5 years, with a median of -$1.3 million in 2023.
• Annual changes were most pronounced in 2022 — Net Income towards Common Stockholders tumbled 3624.47% — and 2025, when it jumped 124.71%.
• Sunshine Biopharma's Net Income towards Common Stockholders stood at -$23.5 million in 2022, then soared by 94.68% to -$1.3 million in 2023, then plunged by 72.65% to -$2.2 million in 2024, then advanced by 0.8% to -$2.1 million in 2025, then jumped by 41.9% to -$1.2 million in 2026.
• The last three Net Income towards Common Stockholders figures came in at -$1.2 million (Q1 2026), -$2.1 million (Q4 2025), and $295951.0 (Q3 2025), per Business Quant data.